Adverse Drug Reaction Classification System

         

ADR Ontology
ADR Term Nephrogenic diabetes insipidus
ADR ID BADD_A03020
ADR Hierarchy
14      Metabolism and nutrition disorders
14.05      Electrolyte and fluid balance conditions
14.05.07      Antidiuretic hormone related conditions
14.05.07.002      Nephrogenic diabetes insipidus
20      Renal and urinary disorders
20.05      Nephropathies
20.05.03      Nephropathies and tubular disorders NEC
20.05.03.010      Nephrogenic diabetes insipidus
Description A genetic or acquired polyuric disorder characterized by persistent hypotonic urine and HYPOKALEMIA. This condition is due to renal tubular insensitivity to VASOPRESSIN and failure to reduce urine volume. It may be the result of mutations of genes encoding VASOPRESSIN RECEPTORS or AQUAPORIN-2; KIDNEY DISEASES; adverse drug effects; or complications from PREGNANCY. | Congenital nephrogenic diabetes insipidus associated with mutations of AQUAPORIN-2. | X-linked congenital nephrogenic diabetes insipidus disorders occurring mostly in males and associated with V2 RECEPTOR mutations. [MeSH]
MedDRA Code 10029147
MeSH ID D018500
ADR Severity Grade (FAERS)
ADR Severity Grade (CTCAE) Not Available
Synonym
Diabetes insipidus nephrogenic | Diabetes nephrogenic (excludes glycosuria) | Nephrogenic diabetes insipidus | Diabetes Insipidus, Nephrogenic | Nephrogenic Diabetes Insipidus | Nephrogenic Diabetes Insipidus, Type II | Diabetes Insipidus, Nephrogenic, Type II | Diabetes Insipidus, Nephrogenic, Autosomal | Congenital Nephrogenic Diabetes Insipidus | Nephrogenic Diabetes Insipidus, Type I | Diabetes Insipidus, Nephrogenic, Type 1 | Diabetes Insipidus, Nephrogenic, Type I | Diabetes Insipidus, Nephrogenic, X-Linked | Acquired Nephrogenic Diabetes Insipidus | ADH-Resistant Diabetes Insipidus | Vasopressin-Resistant Diabetes Insipidus | Diabetes Insipidus Renalis
Drugs Leading to the ADR
Drug IDDrug NameADR Frequency (FAERS)ADR Severity Grade (FAERS)
BADD_D00132Amphotericin b--
BADD_D00230Bendamustine0.000112%
BADD_D00474Cisplatin0.000112%
BADD_D00549Cyclophosphamide--
BADD_D00560Cytarabine0.000168%
BADD_D00605Demeclocycline--
BADD_D00606Demeclocycline hydrochloride--
BADD_D00749Efavirenz--
BADD_D00766Emtricitabine--
BADD_D00964Foscarnet sodium--
BADD_D01083Hydrochlorothiazide0.000035%
BADD_D01133Ifosfamide0.000224%
BADD_D01303Lithium carbonate0.010654%
BADD_D01304Lithium cation0.006471%
BADD_D01305Lithium hydroxide--
BADD_D02015Sevoflurane0.000893%
BADD_D02073Streptozocin--
BADD_D02105Tacrolimus0.000594%
BADD_D02150Temozolomide0.000336%
BADD_D02154Tenofovir0.003877%
BADD_D02155Tenofovir disoproxil--
BADD_D02156Tenofovir disoproxil fumarate--
BADD_D02246Tolvaptan0.000087%
The 1th Page    1    Total 1 Pages
ADReCS-Target
ADR Term Drug Name Target